Takeda invests $900 million in company with the Russian co-owners

Immusoft will receive investments on development drugs for treatment of rare diseases the Japanese producer of Takeda drugs received an option for licensing of development the American companies Immusoft and investment in creation of preparations for treatment of the rare neurometabolic diseases breaking work of the central nervous system. The general investments Japanese group can make $900 million, is told in the joint message of Immusoft and RBV Capital fund (in its portfolio a minority share in Immusoft). The fund is created by the owner JOINT-STOCK COMPANY "R-FARM" Alexey Repik and the Russian venture company (RVK)...